
Verona Pharma plc VRNA
$ 68.06
6.02%
Quarterly report 2024-Q3
added 11-04-2024
Country |
![]() |
IPO year |
2017 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
CEO |
Dr. David S. Zaccardelli |
Employees in the company |
33 |
Shares |
634 M |
Market Cap[1] |
$ 43.2 B |
EBITDA (LTM) |
$ -81.8 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.